Vasomedical Gains CHF Indication For Noninvasive Counterpulsation Therapy
This article was originally published in The Gray Sheet
Executive Summary
A new congestive heart failure indication could create a 10-fold increase in the number of patients eligible for Vasomedical's EECP counterpulsation therapy system
You may also be interested in...
ACC Annual Scientific Session In Brief
COMPASS-HF: Remote monitoring with Medtronic's investigational Chronicle implantable hemodynamic monitor (IHM) is associated with 41% fewer heart-failure related hospitalizations compared with optimal medical management alone in the 274-patient, 28-center randomized COMPASS-HF (Chronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Failure) study. Enrollees had NYHA Class III or IV heart failure and made at least one heart failure-related hospital trip in the last six months. Robert Bourge, MD, University of Alabama-Birmingham, presented the study results at the American College of Cardiology Annual Scientific Session in Orlando March 8...
ACC Annual Scientific Session In Brief
COMPASS-HF: Remote monitoring with Medtronic's investigational Chronicle implantable hemodynamic monitor (IHM) is associated with 41% fewer heart-failure related hospitalizations compared with optimal medical management alone in the 274-patient, 28-center randomized COMPASS-HF (Chronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Failure) study. Enrollees had NYHA Class III or IV heart failure and made at least one heart failure-related hospital trip in the last six months. Robert Bourge, MD, University of Alabama-Birmingham, presented the study results at the American College of Cardiology Annual Scientific Session in Orlando March 8...
Vasomedical EECP Heart Failure PMA Study Redirected Toward CMS Coverage
Vasomedical will use cost data from its prospective evaluation of EECP in congestive heart failure (PEECH) trial to support a national Medicare coverage request for counterpulsation therapy